JP7211938B2 - 免疫原性アルギナーゼペプチド - Google Patents

免疫原性アルギナーゼペプチド Download PDF

Info

Publication number
JP7211938B2
JP7211938B2 JP2019518424A JP2019518424A JP7211938B2 JP 7211938 B2 JP7211938 B2 JP 7211938B2 JP 2019518424 A JP2019518424 A JP 2019518424A JP 2019518424 A JP2019518424 A JP 2019518424A JP 7211938 B2 JP7211938 B2 JP 7211938B2
Authority
JP
Japan
Prior art keywords
seq
arginase
peptide
cells
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537562A (ja
JP2019537562A5 (enExample
Inventor
ハルド アンデルセン，マッズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of JP2019537562A publication Critical patent/JP2019537562A/ja
Publication of JP2019537562A5 publication Critical patent/JP2019537562A5/ja
Application granted granted Critical
Publication of JP7211938B2 publication Critical patent/JP7211938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019518424A 2016-10-07 2017-10-06 免疫原性アルギナーゼペプチド Active JP7211938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16192794.2 2016-10-07
EP16192794 2016-10-07
PCT/EP2017/075443 WO2018065563A1 (en) 2016-10-07 2017-10-06 Immunogenic arginase peptides

Publications (3)

Publication Number Publication Date
JP2019537562A JP2019537562A (ja) 2019-12-26
JP2019537562A5 JP2019537562A5 (enExample) 2020-11-12
JP7211938B2 true JP7211938B2 (ja) 2023-01-24

Family

ID=57123856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019518424A Active JP7211938B2 (ja) 2016-10-07 2017-10-06 免疫原性アルギナーゼペプチド

Country Status (18)

Country Link
US (3) US10858642B2 (enExample)
EP (2) EP4406613A3 (enExample)
JP (1) JP7211938B2 (enExample)
KR (1) KR102674521B1 (enExample)
CN (1) CN109890399A (enExample)
AU (1) AU2017341112B2 (enExample)
DK (1) DK3522905T3 (enExample)
ES (1) ES2992031T3 (enExample)
FI (1) FI3522905T3 (enExample)
HR (1) HRP20241486T1 (enExample)
HU (1) HUE069077T2 (enExample)
IL (1) IL265805B2 (enExample)
LT (1) LT3522905T (enExample)
MX (1) MX2019003970A (enExample)
PL (1) PL3522905T3 (enExample)
PT (1) PT3522905T (enExample)
SI (1) SI3522905T1 (enExample)
WO (1) WO2018065563A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3522905T3 (pl) 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
GB201815549D0 (en) * 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
US20250161422A1 (en) 2022-02-24 2025-05-22 Io Biotech Aps Arginase 2 vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150315561A1 (en) 2014-04-29 2015-11-05 Bio-Cancer Treatment International Limited Methods and Compositions for Modulating the Immune System with Arginase I
US20160250307A1 (en) 2014-12-23 2016-09-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US20110111424A1 (en) 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
WO2003038444A2 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Biomarkers of liver function
CA2836155A1 (en) 2004-10-29 2006-05-11 Board Of Trustees Of Michigan State University Protection against herbivores
PL3064579T3 (pl) 2008-10-31 2021-07-05 Aerase, Inc. Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
CA2766039A1 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
PL3522905T3 (pl) * 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
CN109890838A (zh) * 2016-10-27 2019-06-14 Io生物技术公司 新的pdl2化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150315561A1 (en) 2014-04-29 2015-11-05 Bio-Cancer Treatment International Limited Methods and Compositions for Modulating the Immune System with Arginase I
US20160250307A1 (en) 2014-12-23 2016-09-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

Also Published As

Publication number Publication date
WO2018065563A1 (en) 2018-04-12
EP4406613A3 (en) 2024-10-23
HUE069077T2 (hu) 2025-02-28
JP2019537562A (ja) 2019-12-26
MX2019003970A (es) 2019-12-05
CA3039510A1 (en) 2018-04-12
CN109890399A (zh) 2019-06-14
HRP20241486T1 (hr) 2025-01-03
SI3522905T1 (sl) 2025-02-28
PL3522905T3 (pl) 2025-01-07
KR102674521B1 (ko) 2024-06-11
US11981944B2 (en) 2024-05-14
IL265805B2 (en) 2024-08-01
KR20190077381A (ko) 2019-07-03
IL265805B1 (en) 2024-04-01
AU2017341112B2 (en) 2024-06-27
EP3522905B1 (en) 2024-09-25
US20210139877A1 (en) 2021-05-13
EP3522905A1 (en) 2019-08-14
EP4406613A2 (en) 2024-07-31
US20190338270A1 (en) 2019-11-07
US20240167013A1 (en) 2024-05-23
PT3522905T (pt) 2024-10-02
AU2017341112A1 (en) 2019-05-02
FI3522905T3 (fi) 2024-10-31
DK3522905T3 (da) 2024-10-21
LT3522905T (lt) 2024-11-11
IL265805A (en) 2019-06-30
US10858642B2 (en) 2020-12-08
ES2992031T3 (es) 2024-12-05

Similar Documents

Publication Publication Date Title
US11981944B2 (en) Immunogenic arginase peptides
JP4926714B2 (ja) Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
US20210401976A1 (en) Immunogenic peptides with improved oxidoreductase motifs
JP2020509067A (ja) 糖尿病の治療のためのペプチド及び方法
US20250236658A1 (en) Pdl2 compounds
KR20230142704A (ko) 암 면역요법을 위한 조직 특이적 항원
CN113966342A (zh) TGF-β疫苗
CA3211565A1 (en) Uses of amphiphiles in immune cell therapy and compositions therefor
JP2019527676A (ja) 癌ワクチンにおける使用のためのｐｄｌ１ペプチド
CN119487058A (zh) 膜结合il-15、cd8多肽、细胞、组合物及其使用方法
JP2022507373A (ja) 免疫原性アルギナーゼ２ポリペプチド
JP2022501046A (ja) アルギナーゼ１ポリペプチド
CN113906046A (zh) 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽
HK40012895B (en) Immunogenic arginase peptides
HK40012895A (en) Immunogenic arginase peptides
HK40102519A (en) Tissue-specific antigens for cancer immunotherapy
COCHLOVIUS et al. N. 3 Expression of mutated p21 Ras-~ ptides in transfected EBV-Iymphoblasts elicit a strong specific en-response in an autologous

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230112

R150 Certificate of patent or registration of utility model

Ref document number: 7211938

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250